This initial study identified the potential utility of PSAD in differentiating prostate cancer from benign disease with subsequent studies demonstrating a modest improvement in diagnostic accuracy with application of PSAD in addition to PSA [66]. This evidence concerns the gene KLK3 and prostate carcinoma.